F. Hoffmann-La Roche AG said on Thursday its sales in the first quarter of fiscal 2025 reached 15.4 billion Swiss francs, climbing 7% in Swiss francs and 6% at constant exchange rates (CER) from the same period a year earlier. Sales in the pharmaceuticals division grew 8% at CER to 11.95 billion Swiss...
F. Hoffmann-La Roche AG announced on Tuesday that it will invest $50 billion in the United States over the next five years.Roche hopes to strengthen already established manufacturing and open new facilities, starting with Indiana, Pennsylvania, Massachusetts, and California. As part of the...
Stocks of major European pharmaceutical companies, including French Sanofi, British GSK and AstraZeneca, as well as Swiss Roche and Novartis, saw a decline on Wednesday following US President Donald Trump's announcement of a "major tariff" on pharmaceuticals. Trump revealed that Washington...
F. Hoffmann-La Roche AG said on Thursday its annual sales in 2024 reached 60.5 billion Swiss francs, climbing 3% in Swiss francs and 7% at constant exchange rates (CER) from the same period a year earlier. Sales in the pharmaceuticals division grew 8% at CER to 46.2 billion Swiss francs, while...
F. Hoffmann-La Roche AG announced on Tuesday that it is acquiring Poseida Therapeutics Inc. for around $9 per share in cash or $1 billion in total. Shareholders will also receive a non-tradeable contingent value right (CVR) of up to $4 per share, bringing the deal value up to $1.5 billion. The...
Roche Group said on Wednesday that its sales stood at 15.1 billion Swiss francs in the third quarter of 2024, climbing 6% in Swiss francs and 9% at constant exchange rates from the same period a year earlier. Sales in the pharmaceuticals division grew 10% at constant exchange rates to 11.6...
Roche Holding AG announced on Thursday its sales in the first half of the fiscal year 2024 saw no annual change compared to the initial six months of 2023, standing at 29.85 billion Swiss francs.The pharmaceutical company's net income declined by 11% year-on-year to land at 6.7 billion Swiss francs....
F. Hoffmann-La Roche AG revealed on Monday in a press release the changes made to its enlarged Corporate Executive Committee.Head of Roche Pharma Partnering James Sabry will retire after spending 14 years at the company, it was mentioned in the press release. Head of Group Business...
F. Hoffmann-La Roche AG shared on Thursday that the initial phase of its medication CT-388 showed positive results in treating patients dealing with obesity or type 2 diabetes."The results are highly encouraging for further development of CT-388 for both obesity and type 2 diabetes and underscore...
F. Hoffmann-La Roche AG shared on Wednesday that its sales stood at 14.4 billion Swiss francs during the opening quarter of fiscal 2024, marking a 6% decline from the prior-year trimester. At constant currency rates, sales grew by 2% year-over-year."We had a strong start into the year, with both our...
This website uses cookies to ensure you get the best experience. Our Terms of Use and Data Protection Policy explain the data we collect, why we collect them, and how we may share them.
